TheraVida is a biopharmaceutical company focused on the development of new therapies for hyperhidrosis. The company's main product is a proprietary combination drug technology, Anhydrix™, designed to treat primary focal hyperhidrosis with improved tolerability and efficacy. TheraVida's technology has completed a phase 2 human study, indicating progress in the clinical development pipeline. It was founded in 2005 and is based in Chapel Hill, North Carolina.

Paloma Pharmaceuticals, Inc. is a drug development company focusing on pathologies with a vascular component including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (pulmonary fibrosis) endometriosis, osteoporosis and skin diseases (psoriasis and atopic dermatitis). Paloma owns the intellectual property relating to a series of , small molecule drugs created through an integrated design platform incorporating , customized and industry standard computational tools that has therapeutic potential for the treatment of the foregoing diseases.

Curemark is a clinical-stage biopharmaceutical company specializing in the development of novel therapies for neuro-developmental and neurodegenerative disorders. The company offers a range of therapeutic products targeting enzyme deficiencies to address conditions such as Autism Spectrum Disorder, ADHD, addiction, Parkinson’s Disease, and Schizophrenia. Curemark's innovative approach includes a first-in-class treatment for Autism that aims to modify the disorder rather than just manage symptoms. It is based in Rye, New York.

NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

Solidus Biosciences is a company focused on providing business intelligence in the pharmaceutical and biologic drugs sector. The company's main services include offering insights on life cycle management, brand erosion, generic entry, biosimilars, patents, sales, litigation, and more, all related to pharmaceutical and biologic drugs. The company primarily serves the biopharmaceutical industry. It is based in Troy, New York.

Excelimmune specializes in the production of immunity reagents and operates within the biotechnology and healthcare sectors. The company offers a range of products including reagents for measuring antibody avidity, rapid test kits for avian influenza, and kits for cell immortalization. Excelimmune primarily serves the scientific research community and healthcare industry with its array of diagnostic and research tools. It is based in Woburn, Massachusetts.